Press Releases ABIONYX Pharma Börse Stuttgart

Equities

609 FR0012616852

Market Closed - Börse Stuttgart Other stock markets 15:01:47 07/06/2024 BST			5-day change	1st Jan Change
1.146 ^EUR	-1.72%		-1.72%	-36.40%

03-14	Abionyx Pharma: to benefit from a 1ME grant from Bpifrance	CF
03-11	Abionyx: reduced net loss in 2023	CF

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

ABIONYX Pharma Provides an Update on Its Activity and Cash Position for the 1st Quarter 2024	05-16	BU
ABIONYX Pharma: Availability of the Universal Registration Document for the Year 2023	05-02	BU
ABIONYX Pharma - Bpifrance Supports the Development of CER-001 in Ophthalmology With a Nearly €1 Million Non-dilutive Innovation Grant	03-14	BU
ABIONYX Pharma Announces Its 2023 Full-Year Financial Results	03-11	BU
ABIONYX Pharma announces its financial calendar for the year 2024	03-07	BU
ABIONYX Pharma : Inside Information / Other news releases	11-23	PU
ABIONYX Pharma RACERS study in sepsis selected for LateBreaking Clinical Results Poster Presentation at the American Society of Nephrology 2023 Annual Meeting 'Kidney Week'	17/10/23	AQ
ABIONYX Pharma : Inside Information / News release on accounts, results	26/09/23	PU
ABIONYX Pharma : Inside Information / Other news releases	12/07/23	PU
ABIONYX Pharma Reports Positive Results from Phase 2a Pilot Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury	17/01/23	AQ
ABIONYX Pharma : announces its cash position and provides an activity update on the 3rd quarter 2022	17/11/22	PU
ABIONYX Pharma : announces its 2022 half-year financial results	29/09/22	PU
ABIONYX Pharma : Availability of the Universal Registration Document for the year 2021	29/04/22	PU
ABIONYX Pharma : Annual results 2021	28/04/22	PU
ABIONYX Pharma : Inside Information / Other news releases	07/04/22	PU
ABIONYX Pharma : Receives FDA Orphan Drug Designation (ODD) for CER-001 for the Treatment of LCAT Deficiency Presenting as Kidney Dysfunction and/or Ophthalmologic Disease	29/03/22	PU
ABIONYX Pharma : announces positive clinical findings for CER-001 in treating COVID-19, published in Biomedecines, demonstrating that CER-001 limits inflammation effects	24/03/22	PU
ABIONYX Pharma : announces the signing of an agreement for the contribution of 100% of the capital of IRIS Pharma Holding, fully remunerated by the issuance of new shares at a fixed price of 3.60 euros per share	17/11/21	PU
ABIONYX Pharma initiates discussions with IRIS Pharma, a world leader in preclinical and clinical ophthalmology research, with a view to a possible strategic deal	09/11/21	PU
ABIONYX Pharma : Gross cash position and business update for the first half of 2021	06/08/21	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases ABIONYX Pharma Börse Stuttgart

Equities

609

FR0012616852

Press Releases

Filters